Black Diamond Therapeutics opened lower at $1.60, compared with its previous close of $1.61. In the last trading session, the stock traded between $1.55 and $1.64. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Black Diamond Therapeutics is now worth
$ 19.10
Resulting in a loss of
$ 80.90 (80.90%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.10 (-5.90%)
Day High
$1.64
Day Low
$1.55
Day Open
$1.60
Prev Close
$1.61
Volume
8,69,615
1W Return
-20.05%
1M Return
-14.65%
3M Return
-27.68%
6M Return
-48.47%
1Y Return
-67.21%
Fundamentals
Market Cap ($ Mn)
87
PE Ratio
-
PB Ratio
1.33
PEG Ratio
-
ROE
18.77%
ROCE
13.45%
EPS (TTM)
$-0.17
Investment Returns
1 Week
-20.05%
1 Month
-14.65%
3 Months
-27.68%
6 Months
-48.47%
9 Months
-31.76%
Financials
Quarterly
All values in $ Mn
70.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
Black Diamond shares fall 13% despite positive silevertinib Phase 2 data
Shares fell 13.49% to $1.91 despite positive Phase 2 data. Silevertinib showed 86% CNS objective response rate in brain metastases. FDA supports accelerated approval path; Phase 3 starts Q2 2027. Cash balance stands at $102.0 million with $8.3 million quarterly burn.
2 days ago
3Sep
Black Diamond Therapeutics to present at H.C. Wainwright conference
Elizabeth Buck, Ph.D., to lead fireside chat at H.C. Wainwright conference on September 15, 2026. Company to host one-on-one investor meetings alongside the public presentation. Silevertinib has treated over 200 patients in NSCLC and GBM indications. Randomized Phase 2 trial for EGFRvIII-positive GBM initiated in May 2026.
2mo ago
6Aug
Black Diamond Therapeutic Q2 Results: EPS beats estimates by 10.53%
Black Diamond Therapeutic delivered a positive earnings surprise in Q2 with EPS of $(0.17), beating the $(0.19) estimate by 10.53%. The result also marks an improvement over the $(0.19) loss from the same period last year, signaling narrowing losses.
